Welcome to our dedicated page for AC Immune SEC filings (Ticker: ACIU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AC Immune SA filings document a foreign private issuer developing precision therapeutics and diagnostics for neurodegenerative diseases. Recent Form 6-K reports furnish press releases, IFRS financial statements, management discussion and annual statutory and compensation reports, with certain reports incorporated by reference into Form F-3 and Form S-8 registration statements.
The disclosures cover clinical and trial updates for ACI-24, ACI-7104.056, ACI-19764 and ACI-35.030/JNJ-2056; collaboration amendments for Morphomer® Tau small molecules; cash resources and operating requirements; and governance-related compensation reporting. They also record exhibit-based material updates for AC Immune’s active immunotherapy, small-molecule and diagnostic pipeline.
AC Immune reported interim 12‑month data from the first three prodromal Alzheimer’s disease cohorts (AD1–AD3) of the Phase 1b/2 ABATE trial, covering 74 patients treated with its anti‑amyloid beta active immunotherapy ACI‑24. The therapy has been generally safe and well tolerated so far, with no amyloid‑related imaging abnormalities‑edema (ARIA‑E) observed and anti‑Abeta antibody responses detected at all dose levels with a dose response. The company is now testing an enhanced ACI‑24 formulation with an additional adjuvant in the newly initiated Cohort AD4 to further boost immunogenicity. Under its existing option and license agreement with Takeda for anti‑Abeta active immunotherapies, AC Immune received an upfront payment of $100 million and a $12 million milestone on dosing the first patients in Cohort AD4, and may earn up to approximately $2.1 billion in additional milestones plus tiered double‑digit royalties if the program advances to commercialization.
AC Immune SA director Roy Ervin Twyman received equity awards as compensation. On June 11, 2026 he was granted 16,568 restricted share units under the AC Immune SA 2016 Stock Option and Incentive Plan, increasing his holdings to 92,556 common shares, including 66,556 shares underlying outstanding restricted share units.
On the same date he also received share options over 38,889 common shares with an exercise price of $2.62 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036, giving him the right to buy the underlying shares in the future rather than reflecting an open-market purchase.
AC Immune SA director Renee Aguiar-Lucander reported equity compensation awards rather than open-market trades. On June 11, 2026, she received a restricted share unit grant covering 16,568 common shares under the AC Immune SA 2016 Stock Option and Incentive Plan.
Following this grant, 51,136 common shares are underlying her outstanding restricted share units. She was also awarded options for 38,889 common shares at an exercise price of $2.62 per share, which fully vest on June 10, 2027 and expire on June 10, 2036.
AC Immune SA interim CEO Martin Zuegel reported equity compensation awards. On June 11, 2026, he received a grant of 33,136 restricted share units under the company’s 2016 Stock Option and Incentive Plan. Following this award, he holds 71,408 common shares underlying outstanding restricted share units.
On the same date, he was also granted share options on 77,778 common shares at an exercise price of $2.6200 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036. All reported holdings are direct.
AC Immune SA director Monika Buetler received new equity awards as part of her compensation. On June 11, 2026, she was granted 17,751 restricted share units under the AC Immune SA 2016 Stock Option and Incentive Plan. The grant increases her direct interest in the company without any cash purchase.
On the same date, she also received share options for 41,667 common shares at an exercise price of $2.62 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036. After these awards, she directly holds 71,656 common shares, largely reflecting restricted share units rather than open-market buying.
AC Immune SA director June Carl Howard reported new equity compensation grants. On June 11, 2026, she received 16,568 common shares as a restricted share unit grant under the AC Immune SA 2016 Stock Option and Incentive Plan.
Following this award, her direct holdings in common shares were 67,556. She also received share options for 38,889 common shares at an exercise price of $2.62 per share, which fully vest on June 10, 2027 and expire on June 10, 2036. These awards reflect compensation rather than open‑market trading.
AC Immune SA reported that shareholders approved all proposals at the June 2026 Annual General Meeting, including the 2025 IFRS consolidated and statutory financial statements and the 2025 compensation report. Shareholders also discharged the Board and Executive Management and approved maximum compensation of CHF 1.029M for the Board and CHF 6.742M for Executive Management.
The company recorded a 2025 IFRS loss of CHF 70.4M on revenue of CHF 3.6M, increasing accumulated losses brought forward to CHF 424.441M. Liquidity was CHF 91.4M at year-end 2025 and CHF 74.8M as of March 31, 2026, supporting guidance for a cash runway into Q4 2027 with 2026 cash burn of CHF 55–65M. Shareholders approved a new capital band allowing share capital changes between CHF 2,202,018.50 and CHF 2,862,500.00 until June 11, 2031, and increased conditional share capital for employee plans to CHF 150,000.00 (up to 7.5 million shares). The AGM presentation highlighted an Alzheimer’s and Parkinson’s-focused pipeline, multiple FDA Fast Track designations and planned 2026 clinical milestones.
AC Immune SA reported that it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation. The funding will support extending Part 1 of the ongoing Phase 2 VacSYn trial of ACI-7104, its anti‑alpha‑synuclein active immunotherapy, in early Parkinson’s disease.
The company highlights that the extended trial will help generate long‑term safety and efficacy data, particularly for prodromal and early Parkinson’s disease where prolonged treatment is expected. Management describes ACI‑7104 as showing promising interim Phase 2 results with favorable safety, strong antibody responses, target engagement and encouraging clinical signals, with final Part 1 data to week‑104 expected in H2 2026.
AC Immune SA Chief Executive Officer Andrea Pfeifer reported an open-market sale of 10,000 common shares. The trade occurred on May 15, 2026 at a weighted average price of $2.7935 per share, with individual prices ranging from $2.75 to $2.825.
After this sale, Pfeifer directly holds 3,820,288 common shares, which include 1,921,005 common shares underlying outstanding restricted share units. She also reports 14,000 common shares held indirectly by her spouse.
ACIU affiliate files Form 144 to sell 20,000 common shares. The filing lists 20,000 shares proposed for sale and references prior 10b5-1 sales of 10,000 shares on 02/17/2026, 03/16/2026 and 04/15/2026 with the listed proceeds per sale. The notice identifies the shares as previously exercised stock options.